NEW YORK, Aug. 23, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether PetMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 23, 2017, Aurelius Value published a report alleging that the Company targets opioid users with Google ads and other marketing techniques aimed at facilitating the abuse of opioids.
On this news, PetMed's share price has fallen as much as $6.26, or 15.88%, during intraday trading on August 23, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
SOURCE Pomerantz LLP